Specific efficacy of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced neuroendocrine tumours of the small intestine

177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study

(2014) Giovanni Paganelli et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours

(2014) Samer Ezziddin et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Favourable outcomes of 177Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours

(2014) Raghava Kashyap et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Predictors of Long-Term Outcome in Patients with Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy with 177Lu-Octreotate

(2014) S. Ezziddin et al.   JOURNAL OF NUCLEAR MEDICINE

Can peptide receptor radionuclide therapy be safely applied in florid bone metastases?

(2014) A. Sabet et al.   NUKLEARMEDIZIN-NUCLEAR MEDICINE

Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience

(2013) Robert L. Fine et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate

(2013) Amir Sabet et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Outcome and toxicity of salvage therapy with 177Lu-octreotate in patients with metastatic gastroenteropancreatic neuroendocrine tumours

(2013) Amir Sabet et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Long-Term Outcome and Toxicity After Dose-Intensified Treatment with 131I-MIBG for Advanced Metastatic Carcinoid Tumors

(2013) S. Ezziddin et al.   JOURNAL OF NUCLEAR MEDICINE

Long-Term Hematotoxicity After Peptide Receptor Radionuclide Therapy with 177Lu-Octreotate

(2013) A. Sabet et al.   JOURNAL OF NUCLEAR MEDICINE

ENETS Consensus Guidelines for the Management of Patients with Neuroendocrine Neoplasms from the Jejuno-Ileum and the Appendix Including Goblet Cell Carcinomas

(2012) Ulrich-Frank Pape et al.   NEUROENDOCRINOLOGY

ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary

(2012) Marianne Pavel et al.   NEUROENDOCRINOLOGY

The Clinical Relevance of Chromogranin A as a Biomarker for Gastroenteropancreatic Neuroendocrine Tumors

(2011) Ben Lawrence et al.   ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA

Response, Survival, and Long-Term Toxicity After Therapy With the Radiolabeled Somatostatin Analogue [90Y-DOTA]-TOC in Metastasized Neuroendocrine Cancers

(2011) Anna Imhof et al.   JOURNAL OF CLINICAL ONCOLOGY

Response and Long-Term Control of Bone Metastases After Peptide Receptor Radionuclide Therapy with 177Lu-Octreotate

(2011) S. Ezziddin et al.   JOURNAL OF NUCLEAR MEDICINE

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

(2011) Marianne E Pavel et al.   LANCET

Peptide Receptor Radionuclide Therapy with 90Y-DOTATOC and 177Lu-DOTATOC in Advanced Neuroendocrine Tumors: Results from a Danish Cohort Treated in Switzerland

(2011) Andreas Klaus Pfeifer et al.   NEUROENDOCRINOLOGY

Chromogranin A—Biological Function and Clinical Utility in Neuro Endocrine Tumor Disease

(2010) Irvin M. Modlin et al.   ANNALS OF SURGICAL ONCOLOGY

Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy

(2010) Samer Ezziddin et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

90Y-Edotreotide for Metastatic Carcinoid Refractory to Octreotide

(2010) David L. Bushnell et al.   JOURNAL OF CLINICAL ONCOLOGY

131I-Metaiodobenzylguanidine Therapy of Neuroblastoma and Other Neuroendocrine Tumors

(2010) Frank Grünwald et al.   SEMINARS IN NUCLEAR MEDICINE

Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors

(2010) Dik J. Kwekkeboom et al.   SEMINARS IN NUCLEAR MEDICINE

Lymphocytic Toxicity in Patients After Peptide-Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE and 90Y-DOTATOC

(2009) Maribel L. Sierra et al.   CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS

Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study

(2009) A Ahmed et al.   ENDOCRINE-RELATED CANCER

Systemic therapy for neuroendocrine tumours of gastroenteropancreatic origin

(2009) Bristi Basu et al.   ENDOCRINE-RELATED CANCER

Phase II Study of High-Dose [131I]Metaiodobenzylguanidine Therapy for Patients With Metastatic Pheochromocytoma and Paraganglioma

(2009) Sara Gonias et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors

(2008) Ulrich‐Frank Pape et al.   CANCER

Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours

(2008) U.-F. Pape et al.   ENDOCRINE-RELATED CANCER

Efficacy of RAD001 (Everolimus) and Octreotide LAR in Advanced Low- to Intermediate-Grade Neuroendocrine Tumors: Results of a Phase II Study

(2008) James C. Yao et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment With the Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate: Toxicity, Efficacy, and Survival

(2008) Dik J. Kwekkeboom et al.   JOURNAL OF CLINICAL ONCOLOGY